Plus Therapeutics' CNSide Diagnostics Gets CAP Accreditation

Key Highlights

• Plus Therapeutics' subsidiary, CNSide Diagnostics, received accreditation from the College of American Pathologists (CAP).
• CAP accreditation is internationally recognized as the "gold standard" in laboratory accreditation.
• The Houston-based clinical laboratory underwent a rigorous on-site inspection of clinical protocols, quality control, and personnel.
• This accreditation strengthens CNSide Diagnostics' quality framework, building on its CLIA-certified operations.
• It is expected to reinforce clinical confidence in the CNSide® CSF Assay Platform.
• The accreditation aims to advance payer engagement for broader coverage and reimbursement.
• It will also facilitate health system adoption and enable future menu expansion for the CNSide® platform.
• CNSide Diagnostics now joins over 8,000 CAP-accredited laboratories worldwide.